Development of severe bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds

Berkhout, Daniel J. C.; Niemarkt, Hendrik J.; Benninga, Marc A.; Budding, Andries E.; Kaam, Anton H. van; Kramer, Boris W.; Pantophlet, Charlene M; Weissenbruch, Mirjam M. van; Boer, Nanne K. H. de; Meij, Tim G. J. de

doi:10.1038/pr.2017.268

Cited by 30 publications

(41 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal VOCs are considered to reflect microbiota composition, function, and interaction with the host. 1 , 2 They are increasingly considered to have potential as a biomarker in the diagnostic workup and monitoring of various gastrointestinal diseases, e.g., inflammatory bowel disease (IBD), colorectal cancer, and even sepsis. 3 − 11 Various studies have demonstrated the diagnostic potential of VOCs in both pediatric and adult IBD populations by analyzing VOCs deriving from urine, exhaled breath, and feces.…”

mentioning

confidence: 99%

Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry

Bosch¹,

Hassani²,

Covington

et al. 2018

Anal. Chem.

View full text Add to dashboard Cite

Fecal volatile organic compounds (VOCs) are increasingly considered to be potential noninvasive, diagnostic biomarkers for various gastrointestinal diseases. Knowledge of the influence of sampling conditions on VOC outcomes is limited. We aimed to evaluate the effects of sampling conditions on fecal VOC profiles and to assess under which conditions an optimal diagnostic accuracy in the discrimination between pediatric inflammatory bowel disease (IBD) and controls could be obtained. Fecal samples from de novo treatment-naïve pediatric IBD patients and healthy controls (HC) were used to assess the effects of sampling conditions compared to the standard operating procedure (reference standard), defined as 500 mg of sample mass diluted with 10 mL tap water, using field asymmetric ion mobility spectrometry (FAIMS). A total of 17 IBD (15 CD (Crohn's disease) and 2 UC (ulcerative colitis)) and 25 HC were included. IBD and HC could be discriminated with high accuracy (accuracy = 0.93, AUC = 0.99, p < 0.0001). A smaller fecal sample mass resulted in a decreased diagnostic accuracy (300 mg accuracy = 0.77, AUC = 0.69, p = 0.02; 100 mg accuracy = 0.70, AUC = 0.74, p = 0.003). A loss of diagnostic accuracy was seen toward increased numbers of thaw–freeze cycles (one cycle, accuracy = 0.61, AUC = 0.80, p = 0.0004; two cycles, accuracy = 0.64, AUC = 0.56, p = 0.753; and three cycles, accuracy = 0.57, AUC = 0.50, p = 0.5101) and when samples were kept at room temperature for 180 min prior to analysis (accuracy = 0.60, AUC = 0.51, p = 0.46). Diagnostic accuracy of VOC profiles was not significantly influenced by storage duration differences of 20 months. The application of a 500 mg sample mass analyzed after one thaw–freeze cycle showed the best discriminative accuracy for the differentiation of IBD and HC. VOC profiles and diagnostic accuracy were significantly affected by sampling conditions, underlining the need for the implementation of standardized protocols in fecal VOC analysis.

show abstract

mentioning

confidence: 99%

Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry

Bosch¹,

Hassani²,

Covington

et al. 2018

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…The microbiome of breast milk can be "regrown" in pasteurized DHM with the inoculation of unprocessed MOM [58] which awaits clinical testing. BPD has also been associated with changes in the microbiome of the airways [59,60] and may even be associated with the gut microbiome [61].…”

Section: Discussionmentioning

confidence: 99%

Donor Human Milk Protects against Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis

Villamor-Martínez

Pierro

Cavallaro

et al. 2018

Preprint

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most common complication after preterm birth. Pasteurized donor human milk (DHM) has increasingly become the standard of care for very preterm infants over the use of preterm formula (PF) if mother’s own milk (MOM) is unavailable. Studies have reported beneficial effects of DHM on BPD. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies on the effects of DHM on BPD and other respiratory outcomes. Eighteen studies met the inclusion criteria. Meta-analysis of RCT’s could not demonstrate that supplementation of MOM with DHM reduced BPD when compared to PF (3 studies, risk ratio [RR] 0.89, 95% confidence interval [CI] 0.60–1.32). However, meta-analysis of observational studies showed that DHM supplementation reduced BPD (8 studies, RR 0.78, 95% CI 0.67–0.90). An exclusive human milk diet reduced the risk of BPD, compared to a diet with PF and/or bovine milk-based fortifier (3 studies, RR 0.80, 95% CI 0.68–0.95). Feeding raw MOM, compared to feeding pasteurized MOM, protected against BPD (2 studies, RR 0.77, 95% CI 0.62–0.96). In conclusion, our data suggest that DHM protects against BPD in very preterm infants, but pasteurization of human milk reduces the benefit.

show abstract

“…Infants who survive BPD commonly suffer from impaired cognitive functions and lung function abnormalities. Early identification of preterm infants at risk of developing BPD, allows for timely initiation of interventions [13]. Since BPD is a lung disease, exhaled VOCs may be preferred to perform VOC analysis, however, infants suffering from BPD are commonly mechanically ventilated which makes collection of exhaled breath complicated.…”

Section: Bronchopulmonary Dysplasiamentioning

confidence: 99%

“…Several studies have demonstrated the existence of vital cross-talks between different mucosal sites of the body, including bidirectional interaction between gut and lungs, the so-called gut-lung axis [75,76]. Therefore, Berkhout et al aimed to evaluate the potential of fecal VOC by means of eNose (Cyranose 320 ® ) as early non-invasive biomarker for BPD [13]. Fecal VOC profiles were identified at four different time points (7,14,21, and 28 days postnatally) of 15 preterm infants with severe BPD and 15 matched healthy controls.…”

Section: Bronchopulmonary Dysplasiamentioning

confidence: 99%

“…Based on pattern recognition algorithms, obtained VOC-profiles could be compared and potentially discriminated from each other. Therefore, different studies assessed usability of eNose devices in medical diagnostics of various diseases [13][14][15][16][17]. However, the main limitation of such eNose devices is their inability to identify individual VOCs and their concentration, consequently hampering inter-device outcome comparison.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Application of Fecal Volatile Organic Compound Analysis in Clinical Practice: Current State and Future Perspectives

et al. 2018

View full text Add to dashboard Cite

Abstract:Increasing interest is noticed in the potential of volatile organic compound (VOC) analysis as non-invasive diagnostic biomarker in clinical medical practice. The spectrum of VOCs, originating from (patho)physiological metabolic processes in the human body and detectable in bodily excrements, such as exhaled breath, urine and feces, harbors a magnificent source of information. Thus far, the majority of studies have focused on VOC analysis in exhaled breath, aiming at identification of disease-specific VOC profiles. Recently, an increasing number of studies have evaluated the usability of VOC present in the headspace of feces in the diagnostic work-up of a wide range of gastrointestinal diseases. Promising results have been demonstrated particularly in those diseases in which microbiota alterations are considered to play a significant etiological role, such as colorectal carcinoma, inflammatory bowel disease, irritable bowel syndrome, celiac disease and infectious bowel diseases. In addition, fecal VOC analysis seems to have potential as a diagnostic biomarker for extra-intestinal diseases, including bronchopulmonary dysplasia and sepsis. Different methods for VOC analysis have been used in medical studies, such as gas-chromatography mass spectrometry, selected-ion flow tube-mass spectrometry, ion-mobility spectrometry, and electronic nose devices. In this review, the available literature on the potential of fecal VOCs as diagnostic biomarker, including an overview of relevant VOC detection techniques, is discussed. In addition, future hurdles, which need to be taken prior to implementation of VOC analysis in daily clinical practice, are outlined.

show abstract

Development of severe bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds

Cited by 30 publications

References 40 publications

Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry

Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry

Donor Human Milk Protects against Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis

Application of Fecal Volatile Organic Compound Analysis in Clinical Practice: Current State and Future Perspectives

Contact Info

Product

Resources

About